ReviewAnnals of medicine and surgery (2012)2022
Do tumours located in basal segments have better survival than superior segments in lung cancer?
Review in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Prognostic comparison between superior and basal segments in pure-solid non-small cell lung cancer.General thoracic and cardiovascular surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was in patients with lower lobe lung cancer undergone pulmonary resection, are the tumours located in superior segments superior to the tumours in basal segments in terms of survival? We concluded that there were no statistically significant differences in survival and recurrence between superior and basal segments for lung cancer patients, but overall survival and relapse-free survival were worse in superior segment for clinical stage I non-small cell lung cancer (NSCLC) in the right lower lobe, and remained unclear about other stages of lung cancer. In consideration of operation procedure, we speculate that the superior segments had a relatively worse survival in patients with early-stage NSCLC who underwent segmentectomy; likewise, in patients underwent at least lobectomy, survival of the superior segments was not better than that of the basal segments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.